Diseases /

Lymphoproliferative Disorder

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). [1]

Lymphoproliferative disorders most frequently harbor alterations in KMT2D, TP53, CREBBP, BCL2, and TET2 [2].

Most Commonly Altered Genes in Lymphoproliferative Disorder

TP53 Mutation, CREBBP Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and KMT2D Mutation are the most common alterations in lymphoproliferative disorder [2].

Top Alterations in Lymphoproliferative Disorder

Clinical Trials

View Clinical Trials for Lymphoproliferative Disorder

Significant Genes in Lymphoproliferative Disorder

IRAK1 +

JAK2 +

JAK3 +

MYD88 +

TYK2 +

Disease Details

Parent(s)
Hematologic and Lymphocytic Disorder
Children
Atypical Lymphoproliferative Disorder, Lymphocytic Neoplasm, Immunodeficiency-Associated Lymphoproliferative Disorder, and Benign Lymphoproliferative Disorder
OncoTree Name
Lymphoid
OncoTree Code
LYMPH

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.